http://orcid.org/0000-0002-3876-6074
References
- Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483–492.10.1182/blood-2014-03-561381
- Cavalli G, Guglielmi B, Berti A, et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 2013;72(10):1691–1695.10.1136/annrheumdis-2012-202542
- Ferrero E, Belloni D, Corti A, et al. TNF-α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumatology. 2014;53:198–200.10.1093/rheumatology/ket246
- Ferrero E, Corti A, Haroche J, et al. Plasma chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. Oncolmmunology. 2016;5(7):e1181244.
- Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495–500.
- Cangi MG, Biavasco R, Cavalli G, et al. BRAF V600E -mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis. 2015;74:1596–1602.10.1136/annrheumdis-2013-204924
- Cavalli G, Biavasco R, Borgiani B, et al. Oncogene-induced senescence as a new mechanism of disease: the paradigm of Erdheim-Chester disease. Front Immunol. 2014;5(281):1–17.
- Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim-Chester disease. J Clin Oncol. 2015;33(5):411–418.
- Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–430.10.1038/nature08902
- Novik AV, Protsenko SA, Baldueva IA, et al. Vemurafenib-induced progression of breast cancer: a case report and review of the literature. Targ Oncol. 2016;11:235–238.10.1007/s11523-015-0384-7